# MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

> clinical trial · VERIFIED · 2026-08-17

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Non-small Cell Lung Cancer

- Company: Merck Sharp & Dohme LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07431827

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.